Scientific article
Open access

Caffeine therapy for apnea of prematurity

Published inThe New England journal of medicine, vol. 354, no. 20, p. 2112-2121
Publication date2006

Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.

  • Apnea/drug therapy/therapy
  • Bronchopulmonary Dysplasia/prevention & control
  • Caffeine/pharmacology/therapeutic use
  • Central Nervous System Stimulants/pharmacology/therapeutic use
  • Combined Modality Therapy
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases/drug therapy
  • Infant, Very Low Birth Weight
  • Logistic Models
  • Male
  • Oxygen Inhalation Therapy
  • Respiration, Artificial
  • Weight Gain/drug effects
Citation (ISO format)
SCHMIDT, Barbara et al. Caffeine therapy for apnea of prematurity. In: The New England journal of medicine, 2006, vol. 354, n° 20, p. 2112–2121. doi: 10.1056/NEJMoa054065
Main files (1)
Article (Published version)
ISSN of the journal0028-4793

Technical informations

Creation01/29/2015 3:45:00 PM
First validation01/29/2015 3:45:00 PM
Update time03/14/2023 10:52:05 PM
Status update03/14/2023 10:52:04 PM
Last indexation01/16/2024 4:51:26 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack